On October 29, 2024 Revitope Oncology Inc. (Revitope), a biotechnology company advancing a new class of precision cancer immunotherapies, reported that it has signed a license agreement providing Genmab A/S (Genmab) access to Revitope’s conditional TCE technology, TwoGATE (Press release, Revitope Oncology, OCT 29, 2024, View Source [SID1234647495]). Genmab is granted exclusive rights to utilize TwoGate for multiple drug target pairs during a multi-year research period, including the option to take up to three exclusive licenses for worldwide development and commercialization of the resulting products.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
TwoGATE leverages the dual antigen binding requirement of a unique split paratope that assembles on the tumor cell surface to potently engage T cells with high precision, potentially addressing key areas of unmet need in the treatment of solid tumors.
"The unique blending of precision protein engineering in TwoGATE with target pairs that are exquisitely tailored to solid tumors with high unmet need, offers the potential to transform treatment of solid tumors by allowing TCEs to be dosed at levels that achieve significant efficacy without inducing systemic toxicities," said Werner Meier, Chief Scientific Officer of Revitope. "Genmab is the ideal partner to bring this potential to patients."
"We are thrilled to partner with Genmab, a leading biotechnology company," said Mark Clement, Chief Operating Officer of Revitope. "In deploying our cutting-edge TwoGATE technology platform together with Genmab’s robust antibody engineering and development capabilities, Revitope aims to strengthen Genmab’s pipeline, thereby aiding the transformation of cancer treatment."
Financial Terms
Revitope will receive an upfront payment of USD $9 million and, on a target pair-by-target pair basis, is eligible to receive option-exercise fees and development, regulatory and commercial milestone payments up to USD $600 million -if all three options are triggered- plus tiered, single-digit royalties on commercial sales.